Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ZR-202-CoV in Adults ≥60 Years
NCT05313022Phase 2Unknown
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ZR202-CoV in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
ZR202-CoV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05313022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313022.